Applications of AI in healthcare, including medical diagnostics, drug discovery, patient care solutions, and biotechnology research.
Proteotype Diagnostics has been selected as an industrial beneficiary in the EU-funded HER-CARE Marie Skłodowska-Curie Doctoral Network, joining leading European cancer research institutions to advance early detection and personalized treatment strategies for hereditary and early-stage breast cancer.
Neurava has received a $4 million NIH Blueprint MedTech Optimizer award to create a quantitative algorithm for assessing and forecasting SUDEP risk in epilepsy patients.
OZMOSI and Planview have announced a partnership to connect structured clinical data with AI portfolio planning, enabling pharmaceutical teams to make faster and more informed R&D decisions.
InVita Healthcare Technologies and Gulf Coast Blood have introduced new capabilities in HemaConnect 2.5 to streamline donor recruitment and scheduling for cell and gene therapy programs.
SamaCare has introduced Medical Benefit Prior Authorization Benchmarks, a dataset that provides quarterly insights into approval rates and time to therapy for specialty medications across medical practices.
Independent Emergency Physicians has made a strategic investment in ConsensioHealth to expand its revenue cycle management platform for emergency medicine. The investment will help scale technology, enhance analytics, and increase transparency for physician groups.
Avenda Health announced that its Unfold AI platform is now included in Medicare Physician Fee Schedules across several Western and Mountain West states, expanding access to AI-guided prostate cancer care in physician office settings.
Heidi, an AI care partner for clinicians, has officially launched in South Africa following organic adoption by over 15,000 clinicians. The platform, which automates clinical documentation and administrative tasks, integrates with local systems and supports offline use in low-connectivity areas.
10x Science has raised $4.8 million in seed funding led by Initialized Capital to develop AI that performs molecular-level protein characterization, aiming to accelerate drug development and expand partnerships across the life sciences.
A peer-reviewed study published in JMIR mHealth and uHealth found that Brook.ai’s AI-supported continuous care model improved hypertension control by 26 percent compared to traditional remote patient monitoring.
Courier Health has raised $50 million in Series B funding led by Oak HC/FT, with participation from Norwest and Work-Bench, to enhance its AI-powered patient experience platform for the life sciences industry.
Ada Health and CUF conducted a real-world study published in NEJM AI showing that three in five patients changed their care decisions after using Ada’s symptom assessment tool, doubling the rate of clinically appropriate care.
Amperos Health has raised $16 million in Series A funding led by Bessemer Venture Partners as it launches its AI platform for automating healthcare claim denial management and revenue recovery.
Shapiro+Raj has introduced Stella.ai, an AI agent designed for life sciences marketing and insights, and appointed Scott Swigart as Chief Product Officer and Amir Kapadia as President to lead its growth.
The Catalight Group and Cognoa have formed a partnership connecting Cognoa's FDA authorized Canvas Dx diagnostic tool with Catalight's national behavioral health network to accelerate autism diagnosis and treatment access.
GRAIL will present new data from the NHS-Galleri trial and PATHFINDER 2 study evaluating its Galleri multi-cancer early detection test at the 2026 ASCO Annual Meeting in Chicago.
OpenProtein.AI, founded by MIT alumni Tristan Bepler and Tim Lu, has launched a no-code platform that enables researchers to design and analyze proteins using AI foundation models. The platform, which includes the PoET protein language model, is available to pharmaceutical companies and academic scientists worldwide.
Viva Biotech discussed the integration of AI and flow chemistry in drug discovery during its recent webinar, showcasing advances in automated synthesis and scalable reaction workflows.
Castle Biosciences announced it will present new data showing that its DecisionDx-Melanoma test can identify early-stage melanoma patients at greater risk of recurrence and poor outcomes. The findings will be shared at the European Congress of Dermato-Oncology and the American College of Mohs Surgery meetings.
VytlOne has launched VytlAIQ, an AI-powered platform designed to unify data, automate workflows, and provide predictive intelligence for 340B and specialty pharmacy operations.
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
